(Q46106469)

19 December 2017

meta-analysis

0 references

title

Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends (English)

1 reference

19 December 2017

1 reference

Michael R Manuel

1

1 reference

19 December 2017

Lee-May Chen

series ordinal

2

1 reference

19 December 2017

Aaron B Caughey

series ordinal

3

1 reference

19 December 2017

Leslee L Subak

series ordinal

4

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

19 December 2017

published in

Gynecologic Oncology

1 reference

19 December 2017

volume

93

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

1-8

1 reference

19 December 2017

Health spending projections for 2001-2011: the latest outlook

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The economic burden of gynecologic cancers in California, 1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

A clinician's guide to cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Measuring cost-effectiveness of surgical procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Benefits and costs of using HPV testing to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The Dutch Deep Hyperthermia Trial: results in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Early withdrawal from cervical cancer screening: the question of cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Impact of increasing Papanicolaou test sensitivity and compliance: a modeled cost and outcomes analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening*1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of treatment of early stage endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Measurement of the cost of screening for cervical cancer in the district of Florence, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Interactive neural-network-assisted screening. An economic assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-Effectiveness Analysis of Diagnosis and Management of Cervical Squamous Intraepithelial Lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Comparing two modalities of management of women with cytologic evidence of squamous or glandular atypia: early repeat cytology or colposcopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

PAPNET-assisted rescreening of cervical smears: cost and accuracy compared with a 100% manual rescreening strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Economic evaluation of hybrid capture human papillomavirus testing in women with low-grade papanicolaou smear abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The cost-effectiveness of cervical-vaginal rescreening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effective analysis of mass screening for cervical cancer in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

A cost-effectiveness analysis of cervical cancer screening: health policy implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost effectiveness of cervical cancer screening for the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Economic aspects of cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Evaluation of three cervical cancer detection programs in Japan with special reference to cost-benefit analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost benefit analysis of radiological protection: a case study of remote after-loading in gynaecological radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Control of cancer of the uterine cervix by cytologic screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

An update on cost-effectiveness analysis in critical care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Cost-effectiveness analysis in radiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

Economic analyses in obstetrics and gynecology: a methodologic evaluation of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

A cost-benefit analysis of colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.01.030

1 reference

19 December 2017

1 reference

19 December 2017